Compare AU
Compare CURE vs. QFN
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the BetaShares Australian Financials Sector ETF (QFN). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | QFN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 23 |
Median incremental investment | $619.50 | $540.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,456.00 | $2,141.25 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | QFN | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | QFN.AX was created on 2010-12-10 by BetaShares. The fund's investment portfolio concentrates primarily on financials equity. The ETF currently has 60.74m in AUM and 27 holdings. QFN.AX aims to track the performance of an index (before fees and expenses) comprising the largest ASX-listed companies in the financial sector, including the Big 4 banks and insurance companies but excluding Real Estate Investment Trusts. |
Top 3 holdings | Natera Inc (3.33 %) Incyte Corp (2.96 %) Gilead Sciences Inc (2.80 %) | COMMONWEALTH BANK OF AUSTRALIA (29.78 %) NATIONAL AUSTRALIA BANK LTD (15.53 %) WESTPAC BANKING CORP (13.12 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Financials (99.61 %) Communication Services (2.56 %) Other (0.39 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | Australia (99.69 %) United States (0.31 %) |
Management fee | 0.45 % | 0.34 % |
Key Summary
CURE | QFN | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | Solactive Australia Financials Ex-REITs Sector Index |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.34 % |
Price | $51.97 | $16.96 |
Size | $36.301 million | $88.853 million |
10Y return | N/A | 45.83 % |
Annual distribution yield (5Y) | 4.24 % | 5.63 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 15/12/2010 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | QFN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 83 | 23 |
Median incremental investment | $619.50 | $540.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,456.00 | $2,141.25 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | QFN | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | QFN |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |